QUM From The Start For Healthy Outcomes

How the principles of Quality Use of Medicines can be built into the discovery, development and marketing of medicines for better health outcomes

REGULATORY

APPROVAL

and efficacy data

MEDICINES PATHWAY

prescription, over-the-counter and complementary

SELECTION OF MOLECULE

Search for active

CLINICAL TRIALS

PHASE II

100-200 people with targeted disease

early in development

500-5,000 people with targeted disease

MARKET ENTRY

REIMBURSEMENT

POST MARKET ENTRY

POST-MARKETING STUDIES AND MONITORING

PATENT EXPIRY

EXAMPLES OF ACTIVITIES THAT LEAD TO ENHANCED QUM

QUM MEANS:

Selection of a novel mechanism utilising a disease pathway that has high unmet therapeutic and

benefit over existing therapies

After finding potential substance optimise efficacy and safety profiles

For example:

Discovery of statins to reduce hypercholesterolaemia . Discovery of atenolol elimina

Discovery of fexofenadine, the active metabolite of terfenadine, that is not associated with adverse cardiac effects

 Development of a herbal extract with enhanced concentration of active constituents, such as proprietary St Johns Wort extracts

Identify lead compound with a simple and cost effective synthetic

vs cimetidine given five times daily

Ensure herbal extract can be manufactured consistently from variable biological starting material
For example:
Proprietary St Johns Wort

serious visual side effects of extracts

Select generic and brand name that will maximise QUM by reducing consumer

Identify lead compound that has a dosage regimen conducive to maximising patient adherence For example:
Ranitidine given twice daily

Test that lead compound has therapeutic and pharmacokinetic profile that enables formulation to maximise convenience of dosage and administration

PHASE 1

For example:

A liquid formulation of a drug for use in children or once dail dosage with food

humans of traditional medicines o

Choose target population that best demonstrates therapeutic benefits of medicine health outcomes

Consider selecting people more representative of target population Ensure appropriate dose finding studies are carried out so that correct clinical dose is identified

manufacturing process

against current best practice

Select simplest and most

select and use the best treatment Select packaging format that optimises usability and storage
For example:

Application of consumer-

Ensure PI, CMI and labelling are clearly written and designed, consistent with QUM principles, so that health care professionals

focused labelling Dose aids such as calendar packs, counters on turbuhalers accuhalers to assist in correct

use of medicines Encourage regulators to facilitate timely and appropriate access for patients with high unmet medical Generate, capture and analyse evidence on clinical use and, where appropriate, use to suppor rescheduling

> Ensure scheduling of medicine accurately reflects the established safety and efficacy profile and improves access for target

Develop educational programs counselling aids for medicines rescheduled to OTC status For example:

· Orlistat, fluconazole

Consider flexible scheduling according to individual consumer

knowledge and willingness to

PBS reimbursement application identifies appropriate place in therapy and target population, effectiveness of the medicine and

outcomes For example: Montelukast for asthma

Monitor use of medicines

to ensure predicted cost-effectiveness is achieved in practice

Identify partners and processes that can assist in developing educational and information programs to support appropriate Ensure the medicine reaches the

right patient and is prescribed according to its position in the QUM treatment pathway

For example:

· Patient support programs to improve management of conditions including adherence to treatment plan, such as weight loss programs, smoking cessation, cholesterol lowering,

· QUM built into industry Codes of Conduct; continual review/improvement of these documents · Medicines Australia Continuing

Education program for sales representatives

effectiveness and tolerability of medicines when used as part of "usual" practice

Observe outcomes in post marketing surveillance to further inform the safe, efficacious and cost-effective use of these medicines

For example:

Risk management plans for ne medicines

of PI and CMI . Specific data capture for particular products and events such as addiction

Intellectual property laws must be finely balanced to respect innovation while ensuring timely access to generic medicines to maintain optimal cost-effectiveness of all medicines